To the full analysis
Buyback calculator for Pharming Group
Pharming Group stock: key metrics
PHARM.ASPharming Group had an operating margin of 5.6% and a return on invested capital (ROIC) of 5.5% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | −3,961.2% | −12,024.5% | −16,606.1% |
| 2007 | −104.1% | −3,524.5% | −3,136.4% |
| 2008 | −114.0% | −3,808.0% | −5,494.0% |
| 2009 | −378.1% | −2,525.6% | −4,191.0% |
| 2010 | −85.7% | −4,305.4% | −8,778.8% |
| 2011 | −17.7% | −480.1% | −440.0% |
| 2012 | 81.5% | −155.0% | −300.2% |
| 2013 | 78.8% | −102.5% | −303.9% |
| 2014 | 81.4% | 13.1% | −33.1% |
| 2015 | 50.6% | −119.9% | −100.5% |
| 2016 | 70.5% | −72.7% | −110.5% |
| 2017 | 82.4% | 23.6% | −85.1% |
| 2018 | 80.8% | 27.6% | 18.5% |
| 2019 | 87.4% | 32.1% | 19.1% |
| 2020 | 87.0% | 35.1% | 17.8% |
| 2021 | 83.3% | 9.6% | 7.7% |
| 2022 | 91.5% | 8.9% | 6.7% |
| 2023 | 89.7% | −2.0% | −4.3% |
| 2024 | 88.1% | −1.2% | −4.0% |
| 2025 | 87.9% | 5.6% | 0.8% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −37.1% | −41.8% | −23.4% |
| 2007 | −42.8% | −15.2% | −13.0% |
| 2008 | −100.0% | −17.1% | −39.1% |
| 2009 | −100.0% | −57.8% | −57.4% |
| 2010 | −100.0% | −39.6% | −100.0% |
| 2011 | 200.0% | −49.6% | −53.4% |
| 2012 | 200.0% | −76.5% | −100.0% |
| 2013 | −100.0% | −42.8% | −66.2% |
| 2014 | −23.5% | 6.8% | −10.4% |
| 2015 | −45.7% | −20.0% | −17.3% |
| 2016 | −67.1% | −28.2% | −14.5% |
| 2017 | −100.0% | 32.5% | −45.9% |
| 2018 | 40.5% | 35.7% | 11.7% |
| 2019 | 34.5% | 60.8% | 15.8% |
| 2020 | 22.1% | 54.6% | 9.6% |
| 2021 | 8.0% | 9.5% | 3.9% |
| 2022 | 6.7% | 10.2% | 3.2% |
| 2023 | −4.8% | −2.3% | −2.3% |
| 2024 | −5.3% | −1.7% | −3.0% |
| 2025 | 1.1% | 5.5% | 0.6% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 4 Nov 2026)
- Valuation signal Overvalued since 10 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.